Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmethylsertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 7/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmethylsertraline SCHEMBL29737233 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL29481074 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL4781834 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Dasotraline SCHEMBL29690290 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL263132 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL9611184 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Dasotraline SCHEMBL263142 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL4570539 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL259292 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL29757858 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542961-B1 | TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE FOR USE IN TREATMENT OF CNS DISORDERS | SEPRACOR INC (US) | 2013-09-11 | — | — | EP | claimed |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-06 | — | — | US | claimed |
| CN-114703492-A | Dasotriprin electrochemical preparation method | 湖南大学 | 2022-07-05 | — | — | CN | disclosed |
| US-20210046021-A1 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE | SUNOVION PHARMACEUTICALS INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210046021-A1 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE | SUNOVION PHARMACEUTICALS INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10702486-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | SUNOVION PHARMACEUTICALS INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702486-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | SUNOVION PHARMACEUTICALS INC. (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2020025646-A1 | AN OMEGA-TRANSAMINASE ENZYME | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK (IE) | 2020-02-06 | — | — | WO | disclosed |
| EP-3604507-A1 | AN OMEGA-TRANSAMINASE ENZYME | University College Cork-National University of Ireland, Cork (IE) | 2020-02-05 | — | — | EP | disclosed |
| US-10328036-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10328036-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-25 | — | — | US | disclosed |
| WO-2007006797-A1 | USE OF 4-(3,4-DICHLORO-PHENYL)-1,2,3,4-TETRAHYDRO-NAPHTALEN-1-YLAMINE FOR TREATING CANCER | ANCERIS (FR) | 2007-01-18 | — | — | WO | disclosed |
| US-20060216799-A1 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | SEPRACOR INC. (US) | 2006-09-28 | — | — | US | disclosed |
| US-7105699-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | SEPRACOR INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7087785-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | SEPRACOR INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060128993-A1 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | SEPRACOR INC. (US) | 2006-06-15 | — | — | US | disclosed |
| US-20060014982-A1 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | SEPRACOR INC. (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1542961-A1 | TREATMENT OF CNS DISORDERS WITH TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE AND ITS FORMAMIDE | Sepracor, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040092605-A1 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | SEPRACOR, INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2004024669-A1 | TREATMENT OF CNS DISORDERS WITH TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE AND ITS FORMAMIDE | SEPRACOR, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046021-A1 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE | NLN, TPH1, SLC6A3 | SLC6A2 13/4885SLC6A4 10/4885SLC6A3 3/4885 |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | HTR4, HTR1D, HTR1A | SLC6A2 52/4885SLC6A4 21/4885SLC6A3 60/4885 |
| US-10702486-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | NLN, TPH1, SLC6A3 | SLC6A2 13/4885SLC6A4 10/4885SLC6A3 3/4885 |
| US-10328036-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | NLN, TPH1, SLC6A3 | SLC6A2 13/4885SLC6A4 10/4885SLC6A3 3/4885 |
| US-20040092605-A1 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | PNMT, TPH1, NAT1 | SLC6A2 6/4885SLC6A4 5/4885SLC6A3 7/4885 |
| US-20060014982-A1 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | PNMT, TPH1, NAT1 | SLC6A2 4/4885SLC6A4 6/4885SLC6A3 5/4885 |
| US-20060216799-A1 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | PNMT, TPH1, NAT1 | SLC6A2 4/4885SLC6A4 6/4885SLC6A3 5/4885 |
| US-20060128993-A1 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | PNMT, TPH1, NAT1 | SLC6A2 4/4885SLC6A4 6/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.